Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › ATTAIN-2 (obesity + T2D)

ATTAIN-2 (obesity + T2D)

Orforglipron · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Orforglipron
Population
t2d
Official title
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Sponsor
Eli Lilly and Company
Phase
3
Registry status
completed · 2023-06 → 2025-08
Participants
1613
Duration
72 weeks
Registry
NCT05872620

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
orforglipron 6 mgt2d721613−5.5 % vs −2.2 %
Δ −3.3 pp
−5.1 % vs −2.5 %
Δ −2.6 pp
−1.2 vs −0.56.1 vs 4.619.1 vs 20.020.1 vs 8.412.8 vs 3.87.3 vs 8.8—verified
orforglipron 12 mgt2d721613−7.8 % vs −2.2 %
Δ −5.6 pp
−7.0 % vs −2.5 %
Δ −4.5 pp
−1.5 vs −0.510.6 vs 4.622.3 vs 20.031.1 vs 8.420.2 vs 3.810.3 vs 8.8—verified
orforglipron 36 mgt2d721613−10.5 % vs −2.2 %
Δ −8.3 pp
−9.6 % vs −2.5 %
Δ −7.1 pp
−1.7 vs −0.510.6 vs 4.620.5 vs 20.036.4 vs 8.423.1 vs 3.810.9 vs 8.8—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (24)
  • orforglipron 6 mg · weight_tp · Summary / Table 2 (treatment regimen estimand)
    the mean percent change in bodyweight from baseline to week 72 was –5·1% (95% CI –6·0 to –4·2) with 6 mg (estimated treatment difference [ETD] –2·7 [95% CI –3·7 to –1·6]; p<0·0001)
  • orforglipron 6 mg · weight_eff · Results, efficacy estimand (figure 2B)
    For the efficacy estimand, the mean percent change from baseline in bodyweight to week 72 was -5.5% (95% CI -6.2 to -4.8) or -5.5 kg with orforglipron 6 mg, -7.8% (-8.6 to -7.0) or -7.9 kg with orforglipron 12 mg, -10.5% (-11.5 to -9.6) or -10.4 kg with orforglipron 36 mg, and -2.2% (-2.6 to -1.8) or -2.3 kg with placebo
  • orforglipron 6 mg · ae_dc · Table 4
    Adverse events leading to discontinuation of study drug 20 (6·1%) 35 (10·6%) 34 (10·6%) 29 (4·6%)
  • orforglipron 6 mg · disc_any · Figure 1 trial profile; computed: 63/329 vs 126/630 with placebo
    63 discontinued intervention
  • orforglipron 6 mg · nausea · Table 4
    Nausea 66 (20·1%) 103 (31·1%) 117 (36·4%) 53 (8·4%)
  • orforglipron 6 mg · vomiting · Table 4
    Vomiting 42 (12·8%) 67 (20·2%) 74 (23·1%) 24 (3·8%)
  • orforglipron 6 mg · sae · Table 4
    Serious adverse events 24 (7·3%) 34 (10·3%) 35 (10·9%) 55 (8·8%)
  • orforglipron 6 mg · hba1c · Table 2
    Change in HbA1c, % (95% CI) –1·22 (–1·36 to –1·08) –1·50 (–1·62 to –1·38) –1·66 (–1·77 to –1·55) –0·47 (–0·58 to –0·36) Treatment comparison (95% CI); p value ETD –0·76 (–0·93 to –0·58); p<0·0001 ETD –1·03 (–1·19 to –0·87); p<0·0001 ETD –1·20 (–1·35 to –1·04); p<0·0001
  • orforglipron 12 mg · weight_tp · Summary / Table 2 (treatment regimen estimand)
    –7·0% (–7·8 to –6·2) with 12 mg (ETD –4·5 [–5·5 to –3·6]; p<0·0001)
  • orforglipron 12 mg · weight_eff · Results, efficacy estimand (figure 2B)
    For the efficacy estimand, the mean percent change from baseline in bodyweight to week 72 was -5.5% (95% CI -6.2 to -4.8) or -5.5 kg with orforglipron 6 mg, -7.8% (-8.6 to -7.0) or -7.9 kg with orforglipron 12 mg, -10.5% (-11.5 to -9.6) or -10.4 kg with orforglipron 36 mg, and -2.2% (-2.6 to -1.8) or -2.3 kg with placebo
  • orforglipron 12 mg · ae_dc · Table 4
    Adverse events leading to discontinuation of study drug 20 (6·1%) 35 (10·6%) 34 (10·6%) 29 (4·6%)
  • orforglipron 12 mg · disc_any · Figure 1 trial profile; computed: 74/332 vs 126/630 with placebo
    74 discontinued intervention
  • orforglipron 12 mg · nausea · Table 4
    Nausea 66 (20·1%) 103 (31·1%) 117 (36·4%) 53 (8·4%)
  • orforglipron 12 mg · vomiting · Table 4
    Vomiting 42 (12·8%) 67 (20·2%) 74 (23·1%) 24 (3·8%)
  • orforglipron 12 mg · sae · Table 4
    Serious adverse events 24 (7·3%) 34 (10·3%) 35 (10·9%) 55 (8·8%)
  • orforglipron 12 mg · hba1c · Table 2
    Change in HbA1c, % (95% CI) –1·22 (–1·36 to –1·08) –1·50 (–1·62 to –1·38) –1·66 (–1·77 to –1·55) –0·47 (–0·58 to –0·36) Treatment comparison (95% CI); p value ETD –0·76 (–0·93 to –0·58); p<0·0001 ETD –1·03 (–1·19 to –0·87); p<0·0001 ETD –1·20 (–1·35 to –1·04); p<0·0001
  • orforglipron 36 mg · weight_tp · Summary / Table 2 (treatment regimen estimand)
    –9·6% (–10·5 to –8·7) with 36 mg orforglipron (ETD –7·1 [–8·2 to –6·1]; p<0·0001)
  • orforglipron 36 mg · weight_eff · Results, efficacy estimand (figure 2B)
    For the efficacy estimand, the mean percent change from baseline in bodyweight to week 72 was -5.5% (95% CI -6.2 to -4.8) or -5.5 kg with orforglipron 6 mg, -7.8% (-8.6 to -7.0) or -7.9 kg with orforglipron 12 mg, -10.5% (-11.5 to -9.6) or -10.4 kg with orforglipron 36 mg, and -2.2% (-2.6 to -1.8) or -2.3 kg with placebo
  • orforglipron 36 mg · ae_dc · Table 4
    Adverse events leading to discontinuation of study drug 20 (6·1%) 35 (10·6%) 34 (10·6%) 29 (4·6%)
  • orforglipron 36 mg · disc_any · Figure 1 trial profile; computed: 66/322 vs 126/630 with placebo
    66 discontinued intervention
  • orforglipron 36 mg · nausea · Table 4
    Nausea 66 (20·1%) 103 (31·1%) 117 (36·4%) 53 (8·4%)
  • orforglipron 36 mg · vomiting · Table 4
    Vomiting 42 (12·8%) 67 (20·2%) 74 (23·1%) 24 (3·8%)
  • orforglipron 36 mg · sae · Table 4
    Serious adverse events 24 (7·3%) 34 (10·3%) 35 (10·9%) 55 (8·8%)
  • orforglipron 36 mg · hba1c · Table 2
    Change in HbA1c, % (95% CI) –1·22 (–1·36 to –1·08) –1·50 (–1·62 to –1·38) –1·66 (–1·77 to –1·55) –0·47 (–0·58 to –0·36) Treatment comparison (95% CI); p value ETD –0·76 (–0·93 to –0·58); p<0·0001 ETD –1·03 (–1·19 to –0·87); p<0·0001 ETD –1·20 (–1·35 to –1·04); p<0·0001

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: ATTAIN-2 (obesity + T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.